Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Multiple sclerosis researchers receive NMSS drug development grant

A $500,000 drug development grant from the National Multiple Sclerosis Society was awarded to a partnership between a multiple sclerosis research team at the Icahn School of Medicine at Mount Sinai and Karyopharm Therapeutics Inc., a clinical stage pharmaceutical company. Dr. Patrizia Casaccia, MD, PhD, Professor in the Departments of Neuroscience and Genetics and Genomics, at Icahn School of Medicine at Mount Sinai, will be the academic lead.

21 Nov 2013

National Multiple Sclerosis Society awards grant to MSDF to focus on progressive MS

The National Multiple Sclerosis Society is partnering with the Accelerated Cure Project's Multiple Sclerosis Discovery Forum - an interactive online community and information portal for researchers and clinicians - to develop resources and content focusing on progressive MS. Promoting engagement by the research community on issues in progressive MS is one aspect of a multifaceted approach to increasing progress in this underexplored area of research.

19 Nov 2013

Diplomat selected as provider of IMBRUVICA capsules for MCL treatment

Diplomat, the country's largest independent specialty pharmacy, announced today it is one of five specialty pharmacies selected as a provider of IMBRUVICA (ibrutinib) capsules, approved Nov. 13 by the U.S. Food and Drug Administration for the treatment of Mantle Cell Lymphoma.

16 Nov 2013

People with higher pulse pressure more likely to have Alzheimer's biomarkers in cerebral spinal fluid

People in middle age who have a high blood pressure measure called pulse pressure are more likely to have biomarkers of Alzheimer's disease in their spinal fluid than those with lower pulse pressure, according to research published in the November 13, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.

14 Nov 2013

Merck Serono signs co-development and commercialization agreement for BeiGene-290

Merck Serono, the biopharmaceutical division of Merck, today announced that a global licensing, co-development, and commercialization agreement for BeiGene-290 has been signed with BeiGene Co., Ltd., a biotech research and development company in Beijing, China.

13 Nov 2013

New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients

New data presented at the 6th Pan Asian Committee for Treatment and Research in Multiple Sclerosis, show positive preliminary results from PERSIST, a 12-month, Phase 4 clinical study of once weekly Avonex Pen for patients with relapsing-remitting multiple sclerosis.

13 Nov 2013

New view can give scientists better understanding of how antidepressants work in human brain

Research from Oregon Health & Science University's Vollum Institute, published in the current issue of Nature, is giving scientists a never-before-seen view of how nerve cells communicate with each other.

13 Nov 2013

Furamidine drug may also be useful in treating cancers, immune-related diseases

A class of drugs used to treat parasitic infections such as malaria may also be useful in treating cancers and immune-related diseases, a new WSU-led study has found.

12 Nov 2013

Revalesio to conduct RNS60 Phase IIa clinical trial in RRMS patients

Revalesio Corporation is pleased to announce a new collaboration with noted neurologist Dr. Roland Martin, Head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich. Dr. Martin will be conducting a Phase IIa clinical trial of RNS60 in patients with relapsing-remitting multiple sclerosis.

12 Nov 2013

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

GW Pharmaceuticals plc a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme.

11 Nov 2013

New therapeutic at-home gaming program for stroke patients

Researchers at The Ohio State University Wexner Medical Center have developed a therapeutic at-home gaming program for stroke patients who experience motor weakness affecting 80 percent of survivors.

11 Nov 2013

Research findings may lead to new treatments, approaches for controlling multiple sclerosis

Scientists are gaining a new level of understanding of multiple sclerosis that may lead to new treatments and approaches to controlling the chronic disease, according to new research released today at Neuroscience 2013, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health.

10 Nov 2013

Viewpoints: The battle over one woman's medical story; why Mass. didn't see a wave of cancellations; politicians' love of anecdotes

Edie Littlefield Sundby may not have thought she'd ignite a national debate when the stage-4 cancer survivor asked us to publish her Monday op-ed on losing her oncologist due to the Affordable Care Act. But she certainly has, and it's important to understand why. Mrs. Sundby and millions like her must be denied their medical choices if ObamaCare is going to work as its liberal planners intend (11/6).

8 Nov 2013

Study: Speaking a second language may delay onset of three types of dementias

In the largest study on the topic to date, research shows that speaking a second language may delay the onset of three types of dementias. The research is published in the November 6, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.

7 Nov 2013

GeNeuro's GNbAC1 antibody demonstrates safety profile in Phase 2a study for MS

GeNeuro announced today that its GNbAC1 humanized monoclonal antibody was found to have a very good safety profile when administered to patients with relapsing and progressive forms of Multiple Sclerosis as part of a Phase 2a study.

4 Nov 2013

Neuroimaging findings indicate presence of 'fatigue-network' in individuals with MS

A new study by Kessler Foundation scientists sheds light on the mechanisms underlying cognitive fatigue in individuals with multiple sclerosis. Cognitive fatigue is fatigue resulting from mental work rather than from physical labor.

4 Nov 2013

Aerobic exercise improves memory in individuals with MS, shows study

A research study headed by Victoria Leavitt, Ph.D. and James Sumowski, Ph.D., of Kessler Foundation, provides the first evidence for beneficial effects of aerobic exercise on brain and memory in individuals with multiple sclerosis (MS).

3 Nov 2013

New research reveals iron deposits in brain play a role in pathology of MS

While it's been known for over a century that iron deposits in the brain play a role in the pathology of Multiple Sclerosis (MS), new imaging research from Western University (London, Canada) helps to answer the question of whether these accumulations are a cause or consequence of the disease.

29 Oct 2013

Biogen Idec Q3 total revenues increase 32% to $1.8 billion

Biogen Idec Inc. today reported third quarter 2013 total revenues of $1.8 billion, an increase of 32% over the third quarter of 2012. Non-GAAP diluted EPS for the third quarter of 2013 were $2.35, an increase of 23% over the third quarter of 2012.

28 Oct 2013

DPP-4 inhibitors may reduce risk of autoimmune diseases

Dipeptidyl peptidase-4 inhibitors commonly used to control blood sugar levels in people with type 2 diabetes may also reduce the risk of autoimmune diseases in these patients, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Multiple sclerosis researchers receive NMSS drug development grant

National Multiple Sclerosis Society awards grant to MSDF to focus on progressive MS

Diplomat selected as provider of IMBRUVICA capsules for MCL treatment

People with higher pulse pressure more likely to have Alzheimer's biomarkers in cerebral spinal fluid

Merck Serono signs co-development and commercialization agreement for BeiGene-290

New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients

New view can give scientists better understanding of how antidepressants work in human brain

Furamidine drug may also be useful in treating cancers, immune-related diseases

Revalesio to conduct RNS60 Phase IIa clinical trial in RRMS patients

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

New therapeutic at-home gaming program for stroke patients

Research findings may lead to new treatments, approaches for controlling multiple sclerosis

Viewpoints: The battle over one woman's medical story; why Mass. didn't see a wave of cancellations; politicians' love of anecdotes

Study: Speaking a second language may delay onset of three types of dementias

GeNeuro's GNbAC1 antibody demonstrates safety profile in Phase 2a study for MS

Neuroimaging findings indicate presence of 'fatigue-network' in individuals with MS

Aerobic exercise improves memory in individuals with MS, shows study

New research reveals iron deposits in brain play a role in pathology of MS

Biogen Idec Q3 total revenues increase 32% to $1.8 billion

DPP-4 inhibitors may reduce risk of autoimmune diseases

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in